{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Sideras K"],"funding":["Public Health Service","NCI NIH HHS","National Cancer Institute Department of Health and Human Services"],"pubmed_abstract":["Background
Anthracycline use in metastatic breast cancer (MBC) is hindered by cumulative exposure limits and risk of cardiotoxicity. Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone and anthracyclines, is theorized to exhibit less cardiotoxicity, mainly due to lack of iron binding. We conducted a randomized phase II study to evaluate the efficacy and safety of 2 dosing schedules of pixantrone in patients with refractory HER2-negative MBC.Methods
Intravenous pixantrone was administered at 180 mg/m2 every 3 weeks (group A) versus 85 mg/m2 on days 1, 8, and 15 of a 28-day cycle (group B). Primary endpoint was objective response rate (ORR) and secondary endpoints included progression-free survival (PFS), median 6-month PFS, overall survival ("],"journal":["The oncologist"],"pagination":["oyab065"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9074972"],"repository":["biostudies-literature"],"pubmed_title":["Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)."],"pmcid":["PMC9074972"],"funding_grant_id":["U10 CA180882","P30 CA015083","U10 CA180821","U10CA025224","UG1 CA232760","U10CA180821"],"pubmed_authors":["Liu H","Dueck AC","Mowat RB","Giridhar K","Perez EA","Moreno-Aspitia A","Tenglin RC","Chen B","Sideras K","Gross GG","Ginos BF","Tan W","Hillman DW"],"additional_accession":[]},"is_claimable":false,"name":"Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).","description":"Background
Anthracycline use in metastatic breast cancer (MBC) is hindered by cumulative exposure limits and risk of cardiotoxicity. Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone and anthracyclines, is theorized to exhibit less cardiotoxicity, mainly due to lack of iron binding. We conducted a randomized phase II study to evaluate the efficacy and safety of 2 dosing schedules of pixantrone in patients with refractory HER2-negative MBC.Methods
Intravenous pixantrone was administered at 180 mg/m2 every 3 weeks (group A) versus 85 mg/m2 on days 1, 8, and 15 of a 28-day cycle (group B). Primary endpoint was objective response rate (ORR) and secondary endpoints included progression-free survival (PFS), median 6-month PFS, overall survival (","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-04T10:02:26.696Z","creation":"2025-04-04T10:02:26.696Z"},"accession":"S-EPMC9074972","cross_references":{"pubmed":["35445723"],"doi":["10.1093/oncolo/oyab065"]}}